Clinical Research Currents
  • Home
  • About Us
  • News
    • AI & Machine Learning
    • Alzheimers & Dementia
    • Animal studies
    • Clinical development
    • Clinical science
    • Contract Research Organization
    • Disparities
    • Education
    • Employment
    • FDA
    • FDA Guidance
    • FDA Guidance Documents
    • History
    • Immunotherapy
    • Innovation
    • International
    • Interview
    • Investigator
    • Mobile
    • NIH
    • Operations
    • Patient Perspective
    • Political economy
    • Pre-clinical
    • Precision Medicine
    • Recruitment
    • Regulatory
    • Study Design
    • Wearables
    • Trends
    • Real World Data/Evidence
    • Blockchain
    • Clinical trials
    • Adverse events
    • Technology
  • Calendar
  • Newsletter
  • Resources

2021 Update

Clinical Research Currents has temporarily suspended publication.
Learn about our new clinical trials startup, Sparrow Search, connecting patients with clinical trials.

FDA likely to require substantial clinical data for interchangeable biosimilars, lawyers say

www.raps.org

January 20, 2016
Regulatory

The U.S. Food and Drug Administration is “almost certain) to require clinical data in order for companies to demonstrate interchangeability between a biosimilar and its reference product, thought the question of how much data will be required is major factor in determining how quickly the U.S. biosimilars market will take off, according to a new report from the law firm Goodwin Proctor.

The new EU clinical trials regulation: what you need to know before 2016

xtalks.com

January 11, 2016
Regulatory

New Draft Guidance on best practices for IND communications between sponsors, FDA

www.raps.org

December 8, 2015
FDA Guidance, Regulatory

Investigational new drug application (IND) sponsors communicating with the US Food and Drug Administration (FDA) during the various drug development phases now will have a new set of best practices to consult with prior to their meetings thanks to draft guidance released by FDA on Friday.  (Regulatory Focus, Regulatory Affairs Professionals Society)

 

FDA authorizes first human study to use in vivo genome editing application

www.raps.org

December 8, 2015
Innovation, Regulatory

The US Food and Drug Administration (FDA) broke new ground last week when it authorized the world’s first human clinical trial for an in vivo genome editing application. The investigational new drug (IND) application approval for California-based Sangamo, which is the first and only company to put a gene editing therapy into clinical trials, allows the company to begin conducting in 2016 a Phase 1/2 open-label, dose-escalation study in up to nine male adults with severe hemophilia B. (Regulatory Focus, Regulatory Affairs Professionals Society)

New regulation will drive EU clinical trials, but are you ready for it?

www.outsourcing-pharma.com

November 22, 2015
International, Regulatory

The new EU clinical trial regulation will overhaul the sector according to SynteractHCR, but are CROs prepared for the extra resources and tighter deadlines it will produce?

U.S. plans to require trial consent publication

www.outsourcing-pharma.com

November 22, 2015
Operations, Regulatory

The U.S. government may require companies running clinical trials to post their informed consent forms publicly, under rules proposed by the Department of Health and Human Services (HHS).

FDA seeks comments on mHealth in clinical trials

www.mhealthnews.com

November 22, 2015
Regulatory, Technology

…In an October 29 notice published in the Federal Register, the FDA is seeking input on how mHealth technology might be used to improve clinical trials. The agency is particularly interested in how healthcare providers and other parties are using consumer-generated data, how they’re reaching out to consumers, and whether the data being collected is useful and reliable. (mHealthNews)

Learn from Theranos’s mistakes: an analysis of the Form 483s (Part 1)

www.mddionline.com

November 22, 2015
Regulatory

Startups should heed the Theranos warning: When you raise millions of dollars to develop a product, remember the processes that help get that product to market, including proper implementation of a robust quality management system. (MDDI Online)

U.S. plans to require trial consent publication

www.outsourcing-pharma.com

November 21, 2015
Regulatory

The U.S. government may require companies running clinical trials to post their informed consent forms publicly, under rules proposed by the Department of Health and Human services (HHS). (Outsourcing-Pharma.com)

Current Feature

FDA Notice. October 2015.

November 19, 2015
Regulatory
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • Next Page »

Subscribe to our Newsletter

Get the latest clinical research news delivered straight to your inbox each week.

Submit a Story

Do you have a story you'd like to feature on our website? Share it with us today!

Submit your story

 Join our LinkedIn Group

© 2023 Clinical Research Currents · All Rights Reserved